Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 7 , ISSUE 1 ( January-April, 2015 ) > List of Articles

REVIEW ARTICLE

Cabergoline for Ovarian Hyperstimulation: A Review of Clinical Evidence

Ruchika Garg, Meenal Jain

Citation Information : Garg R, Jain M. Cabergoline for Ovarian Hyperstimulation: A Review of Clinical Evidence. J South Asian Feder Obs Gynae 2015; 7 (1):30-32.

DOI: 10.5005/jp-journals-10006-1317

Published Online: 01-04-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod update 2008;4:321-333.
  2. Dopamine agonist cabergoline reduces hemoconcentration in hyperstimulated women undergoing assisted reproduction. J Clin endocrinal Metab 2007. p. 922931-922937.
  3. How to avoid ovarian hyperstimulation syndrome: a new indication for dopamine agonists. Reprod Biomed Online 2009;18:71-75.
  4. Cabergoline influences ovarian hyperstimulation in hyperprolactemic patient with polycystic ovary syndrome. Hum Reprod 2001;16:2263-2266.
  5. Thromboembolic phenomenon after ovarian stimulation with human menopausal gonadotropin. Lanut 1965;2:1213-1215.
  6. Ovarian hyperstimulation in novel reproductive technologies; prevention and treatment. Fertil Stenil 1992;58249-58261.
  7. The ovarian hyperstimulation syndrome. In: adashi EY, Rock JA, Rosenwakes, editors. Reproductive endocrinology, surgery and technology. Philadelphia, Lippincott-Raven Pub 1996. p. 2225-2232.
  8. Ovarian-hyperstimulation-syndrome epidemiology, pathophysiology, prevention and management. 1st ed. New York: Cambridge University Press 2006. p. 10-33.
  9. Fisher O Inslier Y. Recurrent spontaneous ovarian hyperstimulation syndrome associated with PCOS. Gynecol Endometrial 1995; 9:313-315.
  10. Ovarian hyperstimulation associated with a spontaneous pregnancy. J Obstet Gynaecol 2005;25:394-395.
  11. Weinraub Hyperstimulation syndrome. An update review Obstet Gynecol Surv 1989;44:430-440.
  12. Gerkan, Lali karakocsokmensuer-prevention OHSS: cabergoline versus coasting. Archies of Gynaecol Obstet 2013;288:1159-1163.
  13. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3:255-266.
  14. Dopamine Agonist cabergolin reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinal Metab 2007;92: 2931-2937.
  15. The role of hCG or GnRH-a for prevention of severe OHSS in ART programs Middle East Fertility Society J 2000;5:73-75.
  16. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trial. Am Society of Reproduct Med 2013.
  17. Youssef MA. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur J Obstet Gynecol Reprod Biol 2012;165:254-258.
  18. A comparison of cabergolin and intravenous albumin in the prevention of ovarian hyperstimulation syndrome a randomized controlled trial. J Assist Reprod Genet 2012;29:259-264.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.